Stocktoria
GRAIL, Inc. GRAL
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2024-06-12
GRAIL, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | -382.0% | -1743.0% | -1627.6% |
| Net margin | -277.5% | -1613.9% | -1574.2% |
| FCF margin | -203.8% | -463.7% | -653.8% |
| Return on assets | -14.0% | -67.9% | -37.4% |
| Return on equity | -15.8% | -81.0% | — |
| Current ratio | 11.97 | 10.66 | 0.95 |
| Revenue growth | 17.2% | 34.9% | — |
Source: SEC EDGAR filings · CIK 0001699031 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.